41 results
424B5
GNLX
Genelux Corp
24 May 24
Prospectus supplement for primary offering
5:19pm
payable by us.
We intend to use the net proceeds from this offering for general corporate purposes, which may include research and development … trials of Olvi-Vec in other cancer indications;
discover and develop new product candidates, and conduct research and development activities
424B5
GNLX
Genelux Corp
23 May 24
Prospectus supplement for primary offering
4:59pm
this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures … candidates, and conduct research and development activities, preclinical studies and clinical trials;
manufacture preclinical, clinical
S-3
GNLX
Genelux Corp
2 Feb 24
Shelf registration
4:36pm
strategy, research and development costs; the anticipated timing, costs and conduct of our clinical trials for our only product candidate, Olvi-Vec … from this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures
10-Q
j05fods4q ks4bblse2
15 May 23
Quarterly report
12:00am
10-K
vwtixbdgqnyr1
29 Mar 23
Annual report
5:12pm
FWP
9phck0 bmif
4 Nov 22
Free writing prospectus
3:15pm
S-1/A
yl8boyte
29 Aug 22
IPO registration (amended)
4:01pm
S-1
EX-10.10
c4k8gl32
24 Jun 22
IPO registration
4:35pm
S-1
EX-10.16
qxzhvmj44gytktlyc1
24 Jun 22
IPO registration
4:35pm
S-1
EX-10.19
0gl60b c4j74
24 Jun 22
IPO registration
4:35pm
S-1
jzr9oy
24 Jun 22
IPO registration
4:35pm
S-1
EX-4.4
plzbsoy991b63yra
24 Jun 22
IPO registration
4:35pm